Co-delivery of free vancomycin and transcription factor decoy-nanostructured lipid carriers can enhance inhibition of methicillin resistant Staphylococcus aureus (MRSA) by Hibbitts, Alan et al.
RESEARCH ARTICLE
Co-delivery of free vancomycin and
transcription factor decoy-nanostructured
lipid carriers can enhance inhibition of
methicillin resistant Staphylococcus aureus
(MRSA)
Alan HibbittsID1, Ainhoa Lucı´a2,3, Ine´s Serrano-Sevilla4,5, Laura De Matteis4,5,
Michael McArthur6, Jesu´s M. de la Fuente4,5, Jose´ A. Aı´nsaID2,3, Fabrice Navarro1*
1 University Grenoble Alpes, CEA, LETI, Technologies for Healthcare and Biology division, Microfluidic
Systems and Bioengineering Lab, Grenoble, France, 2 Departamento de Microbiologı´a, Facultad de
Medicina, Universidad de Zaragoza, Zaragoza, Spain, 3 CIBER Enfermedades Respiratorias (CIBERES),
Instituto de Salud Carlos III, Madrid, Spain, 4 Instituto de Nanociencia de Arago´n (INA), Universidad de
Zaragoza, Zaragoza, Spain, 5 CIBER Bioingenierı´a, Biomateriales y Nanomedicina (CIBER-BBN), Instituto
de Salud Carlos III, Madrid, Spain, 6 University of East Anglia, Norwich Medical School, Norwich, United
Kingdom
* fabrice.navarro@cea.fr
Abstract
Bacterial resistance to antibiotics is widely regarded as a major public health concern with
last resort MRSA treatments like vancomycin now encountering resistant strains. TFDs
(Transcription Factor Decoys) are oligonucleotide copies of the DNA-binding sites for tran-
scription factors. They bind to and sequester the targeted transcription factor, thus inhibiting
transcription of many genes. By developing TFDs with sequences aimed at inhibiting tran-
scription factors controlling the expression of highly conserved bacterial cell wall proteins,
TFDs present as a potential method for inhibiting microbial growth without encountering
typical resistance mechanisms. However, the efficient protection and delivery of the TFDs
inside the bacterial cells is a critical step for the success of this technology. Therefore, in our
study, specific TFDs against S. aureus were complexed with two different types of nanocar-
riers: cationic nanostructured lipid carriers (cNLCs) and chitosan-based nanoparticles (CS-
NCs). These TFD-carrier nanocomplexes were characterized for size, zeta potential and
TFD complexation or loading efficiency in a variety of buffers. In vitro activity of the nano-
complexes was examined alone and in combination with vancomycin, first in methicillin
susceptible strains of S. aureus with the lead candidate advancing to tests against MRSA
cultures. Results found that both cNLCs and chitosan-based carriers were adept at com-
plexing and protecting TFDs in a range of physiological and microbiological buffers up to 72
hours. From initial testing, chitosan-TFD particles demonstrated no visible improvements in
effect when co-administered with vancomycin. However, co-delivery of cNLC-TFD with van-
comycin reduced the MIC of vancomycin by over 50% in MSSA and resulted in significant
decreases in viability compared with vancomycin alone in MRSA cultures. Furthermore,
these TFD-loaded particles demonstrated very low levels of cytotoxicity and haemolysis in
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Introduction
Antimicrobial resistance to conventional antibiotics is an increasingly serious threat to global
public health that requires urgent action. Typically, antimicrobial-resistant infections carry
higher incidents of mortality and present a considerable economic burden of over 20 billion
dollars per year in the US alone [1]. This translates to approximately 23,000 deaths in the US
and 33,000 in the EU annually as a direct result of an antimicrobial-resistant infection [1, 2]
with global mortality expected to rise to up to 300 million deaths by 2050 [1]. This is especially
concerning for developing nations as recent studies have predicted a greater tendency for anti-
microbial resistance in Sub-Saharan Africa and parts of South America [3].
Of the multitude of microorganisms currently presenting antimicrobial resistant strains,
Staphylococcus aureus represents a particularly serious challenge to healthcare professionals. S.
aureus is a versatile Gram-positive human pathogen that is commonly found in the respiratory
tract, open wounds and the urinary tract among others [4]. Even prior to the surge in antimi-
crobial resistance, these infections ranged in severity from relatively mild infections of the
skin and soft tissue to life-threatening sepsis such as toxic shock syndrome [4]. The emergence
of strains resistant to methicillin and other antimicrobial agents has added to the cost and
length of treatment resulting in growing concern among medical professionals [5]. This is
especially so in the hospital environment due to the higher mortality rates arising from sys-
temic methicillin-resistant S. aureus (MRSA) infections [6, 7]. Furthermore, the World
Health Organisation (WHO) published recently that there is a high priority for developing
novel antimicrobials against MRSA (https://www.who.int/news-room/detail/27-02-2017-
who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed). Currently in
Europe, rates of MRSA infection can be found to be as high as 24% of hospital patients or 54%
of all S. aureus detected [6, 8]. Resistance to first-line drugs to treat infections caused by S.
aureus is widespread. Patients infected with MRSA are estimated to be 64% more likely to die
than those infected with a non-resistant form of S. aureus.
First approved in 1958 by the FDA, vancomycin is effective against Gram positive bacterial
infections through inhibition of bacterial cell wall synthesis [9, 10]. Vancomycin continues to
be widely used, especially to combat the rising number of MRSA infections that are now
appearing. Although vancomycin has been used for over 40 years, it remains the standard
treatment for infections caused by MRSA with the obvious dangers of this over-reliance now
becoming apparent. Specifically, reports describing clinical failures of vancomycin treatment
due to the emergence of S. aureus with reduced vancomycin susceptibility have now been pub-
lished [11, 12]. Doses of vancomycin needed for treatment of MRSA are now rising and, as a
result, the prospect of treatment associated side effects (particularly nephrotoxicity) must now
be considered for continued successful treatment [13, 14]. In addition, the use of a high dose
vancomycin treatment regime against deep-seated infections has been found to have little to
no impact on MRSA eradication while still resulting in nephrotoxicity [15].
To address the growing threat of antibiotic resistance, effective alternatives to the use of
antibiotics are in high demand [16]. Recent research among the authors has focused on the
development of transcription factor decoys (TFDs) as a new avenue of inhibiting bacterial
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replication. TFDs are short length oligonucleotides (10–80 base pairs) carrying the conven-
tional binding sequence of a bacterial essential transcription factor [17]. When a bacterial cell
is transformed with these molecules, the TFDs outnumber the native promoter binding sites
in the chromosome; hence TFDs competitively bind to the transcription factor proteins, which
will bind less efficiently to the native promoters in the bacterial genome. This in turn inhibits
mRNA production, usually of multiple genes, and consequently the targeted proteins are not
produced (Fig 1). This technology has previously been applied to both eukaryotic and prokary-
otic organisms [18, 19] and presents a potentially new means of MRSA therapy while avoiding
typical antimicrobial resistance mechanisms associated with small molecule drug treatment.
Specifically, our study has focused on the use of a TFD targeted to the WalR transcription
regulator of the WalK/R two-component regulatory system of S. aureus. This protein is highly
conserved and essential for the viability of S. aureus, playing a central role in controlling cell
wall metabolism and membrane composition [20]. In addition, WalK/R has also been reported
to be implicated in resistance to vancomycin [21] and so targeting of this transcription factor
may yield additional benefits such as increasing vancomycin susceptibility of TFD-treated bac-
terial cells.
Like other nucleic acid-based technologies, the successful delivery and protection of the
cargo prior to reaching the inside of the bacteria is an essential step in order to achieve an effi-
cient therapeutic effect. In the case of nucleic acid delivery to Gram-positive S. aureus, it is also
important to consider the cell wall which consists of a phospholipid membrane decorated with
a peptidoglycan layer and is typically 20–40 nm thick. Therefore, this study investigated the
suitability of two different nanoparticle systems to deliver TFDs to both methicillin susceptible
S. aureus (MSSA) and MRSA. The nanocarriers investigated were developed in-house and
consisted of a cationic nanostructured lipid carrier (cNLC) and chitosan-based nanocarrier
(CS-NCs).
The cNLCs consisted of an oil and wax emulsion surrounded by a PEG and cationic lipid
corona (Fig 2A) and the chitosan particles consisted of an oily core with a nanogel polysac-
charidic shell (Fig 2B). Both of these particle systems have previously been found to be suitable
for the delivery of the small molecule antibiotic bedaquiline [22] and it was expected that the
cationic nature of these systems would allow for efficient complexation of the negatively
charged TFD. Following complexation, the TFD-nanoparticles were tested for stability and
changes in physico-chemical characteristics following incubation in a variety of relevant buff-
ers and advanced to an initial in vitro screen of antibacterial activity against a MSSA strain fol-
lowed by testing against an MRSA strain for the best performing TFD-nanoparticles. Crucially,
TFD-nanoparticle complexes were also tested simultaneously with vancomycin over a variety
of doses with the results described herein.
Materials and methods
Materials
Reagents required for formulation were sourced from the same suppliers as previously
described [22]. Tween 20 and absolute EtOH, were purchased from Panreac Quı´mica S.L.U
(Barcelona, Spain). Span 85 (sorbitanetrioleate), oleic acid and chitosan (medium molecular
weight) were purchased from Sigma-Aldrich Pte. Ltd. (Singapore). Bedaquiline was obtained
from AURUM Pharmatech LLC (Franklin Park, NJ, USA). Bis(sulfosuccinimidyl) suberate
(BS3) was purchased from Pierce Biotechnology Inc. (Rockford, IL, USA) and α-methoxy-ω-
amino poly(ethylene glycol) (PEG-MW 5000 Dalton) from IRIS Biotech GmbH (Marktred-
witz, Germany). Myrj S40 (PEG 40 stearate, 1980 Da) and Super Refined Soybean Oil were
obtained from Croda Uniquema (Chocques, France). Suppocire NB was purchased from
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Gattefosse S.A. (Saint-Priest, France). Lipoid S75-3 (soybean lecithin at 69% of phosphatidyl-
choline) and hydrogenated S75 were provided by Lipoid GmbH (Ludwigshafen, Germany).
All the products were pharmaceutical grade and used as received. DOTAP (1,2-dioleoyl-3-
trimethylammonium-propane (chloride salt)) was purchased from Avanti Polar Lipids, Inc.
(Alabaster, Alabama, USA). Water (double processed tissue culture, endotoxin-free) used in
all nanocapsule synthesis was from Sigma-Aldrich.
Transcription factor decoy synthesis
The WalR TFD was manufactured and purified by HPLC at AxoLabs (Kulmbach, Germany).
It consisted of 40 base pairs consisting of the following oligonucleotides: 5’-TGTAATGACA
ATGTAATGTTTTCATTACATTGTCATTACA-3’ (molecular weight 12902) which contains
the two TGTAAT hexamers separated by five nucleotides that are typical of WalR binding sites.
Fig 1. Schematic of nanoparticle-mediated TFD delivery and inhibition of S. aureus replication. A) Normal transcription process whereby (i) the transcription
factor protein (s) bind their relevant promoter region which results in (ii) transcription and mRNA production which is then (iii) translated to functional protein. B)
(i) Following administration of TFD-nanoparticles, (ii) these traverse the bacterial cell wall and membrane and TFD is decomplexed (iii) TFDs competitively inhibit
the transcription factor binding to DNA promotor region in the bacterial chromosome and therefore (iv) considerably reduce or even inhibit transcription and (v)
translation of crucial cell wall proteins (image made in BioRender—biorender.com).
https://doi.org/10.1371/journal.pone.0220684.g001
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Specifically, this binding site is based on the characterized WalR binding stream within the
S. aureus lytM promoter [20] that is recognized by the direct repeat of two similar hexamer
sequences (5’-TGTAAT-3’ and 5’-TGTATT-3’) separated by a 5 bp spacer. The nucleo-
tides were suspended in ultrapure water to a working concentration of 1mg/ml. Similarly, a
negative control TFD was fabricated in the same manner to validate the sequence specific
nature of the TFD. In this case, a 30 base pair length TFD (molecular weight 9655 Da) was
formed as previously described specific for the WhiB7 transcription factor binding site. This
transcription factor is species specific to Mycobacteria [23, 24] and does not play a role in S.
aureus replication or viability.
Cationic nanostructured lipid carrier formulation
cNLCs were formulated using a specific design of experiment approach combined with nanoe-
mulsion and sonication techniques as previously described.[22, 25] Briefly, a premix of soy-
bean oil, Suppocire NC™, lecithin DOPE and DOTAP was weighed and 80 μL of a 10 mM DiD
solution was added for fluorescent particles. The organic premix was then dissolved in CH2Cl2
in a 5 mL vial and the solvent was evaporated at 50 ˚C under a continuous stream of argon.
The continuous aqueous phase, composed of MyrjTM 52 PEG and the appropriate amount
of aqueous buffer (PBS), was prepared separately and added to the vial containing the evapo-
rated organic phase. The vial was placed in a 60˚C water bath and the mixture was sonicated
for 10 min using a VCX750 ultrasonic processor (power output 190 W, 3-mm probe diameter,
Fig 2. Composition of nanoparticles tested for TFD delivery. A) cationic nanostructured lipid carriers and B) chitosan based nanocarrier (CS-NCs) and C) Structure
and properties of the WalR TFD (redrawn from [17, 22]).
https://doi.org/10.1371/journal.pone.0220684.g002
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Sonics). cNLCs were purified via overnight dialysis at room temperature against 1000 times
their volume in the appropriate aqueous buffer (12–14,000 Da MW cut off membranes, Zellu-
Trans). Finally, the cNLC dispersion was filtered through a 0.22 μm Millipore membrane
under aseptic conditions and stored at 4˚C until required.
Formation and physico-chemical characterization of cNLC-TFD
nanocomplexes
cNLC-TFD nanocomplexes were formed using electrostatic interactions at a variety of cNLC
nitrogen to TFD phosphate (N/P) ratios depending on the experimental design. To formulate
nanocomplexes, the desired amount of 1 mg/ ml TFD was incubated at room temperature
with its corresponding amount of cNLC for 20 minutes to allow for spontaneous nanocomplex
formation. For example, for N/P = 32 and a final TFD concentration of 100 nM in 1 ml, it
would be necessary to add 25.27 μl of a 2 mg/ml cNLC solution. Nanocomplexes were then
diluted using the appropriate buffer to the desired final TFD concentration depending on the
experiment (typically 33 nM– 1 μM).
In order to assess the effect of the various buffers used in this study on the cNLC-TFD com-
plex stability, test complexes were formulated in phosphate buffered saline (PBS), tryptic soy
broth (TSB), A549 cell culture medium (Ham0s F12K + 2mM Glutamine + 10% Foetal Bovine
Serum) and human umbilical vein endothelial cell (HUVEC) culture medium (EndoGRO kit
(Millipore)) and examined after 0, 24 and 72hrs for size, zeta potential and complex stability.
Dynamic light scattering was used to determine the particle hydrodynamic diameter and
zeta potential analysis was undertaken using a Zeta Sizer Nano ZS (Malvern Instruments).
cNLC-TFD nanocomplexes were diluted to a TFD concentration of 1 μM in their selected
buffer and were then further diluted 1:50 in 10mM NaCl and transferred in Zeta Sizer Nano
cells (Malvern Instrument) before each measurement. Measurements were performed in tripli-
cate for size analysis and quadruplicate for zeta potential analysis.
cNLC-TFD nanocomplex stability in various buffers was assessed using 4% agarose gel elec-
trophoresis. Nanocomplexes and controls were loaded as well as nanocomplexes that were also
incubated with 0.2 M NaOH at a 50/50 ratio to decomplex any TFD present which will allow
the now decomplexed TFD oligonucleotide to fluoresce under UV light once more. Gels were
run for 20 mins and visualised under UV light for nucleic acid band formation.
Formation and physico-chemical characterization of chitosan-TFD
nanocomplexes
TFD entrapment in chitosan nanocarriers. The general procedure for the preparation of
chitosan nanocarriers used in this work was previously reported [22] and it is based on the for-
mation of a nanoemulsion core coated with a chitosan shell. TFDs were bound to the outer
chitosan polymeric shell of the nanocarrier via electrostatic interaction during nanoemulsion
formation as opposed to later complexation with the finished particles. The first step of nano-
carrier synthesis was identical to the general procedure. Briefly, an organic solution containing
40 mg oleic acid and 8.6 mg Span 85 solved in 4 mL of absolute ethanol was added under mag-
netic stirring to an aqueous solution containing 13.6 mg Tween 20 in 8 mL water. The mixture
was left under stirring during 15 minutes at room temperature for the formation of the nanoe-
mulsion. At this point, 0.5 mL of a 5 mg/mL chitosan solution containing the desired amount
of TFD (50, 100 or 200 μg) was added to the nanoemulsion. TFD solution was prepared in
water at a concentration of 1 mg/mL. The mixture was left 15 minutes more under stirring and
it was finally added to 15 mL of a 50 mM Na2SO4 for the ionotropic gelation of the polymeric
shell. As in the case of nanocarriers without TFD, the solid was separated by ultracentrifugation
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(30 minutes, 69673 G, 10˚C), washed with 10 mL of water, centrifuged again and resuspended
in water. The concentration of the nanocarriers in water suspension was determined by mea-
suring the weight of the sample after freeze-drying. Sterile nanocarriers were prepared in a ver-
tical laminar flow hood and all the reagents and materials used had been previously sterilized
by UV irradiation, washing with 70% Ethanol, filtration through 0.22 μm PVDF filters (Millex
syringe driven filter unit) or by dry heat treatment (180˚C).
Determination of TFD entrapment efficiency and drug loading. The amount of
entrapped TFD was determined by means of agarose gel electrophoresis (20 min at 90V with
1% agarose gels) stained with GelRed and the following analysis of fluorescence intensity of
the band corresponding to TFD using a Gene Genius Syngene Transilluminator and ImageJ
software. Different amounts of free TFD of a known concentration were included to obtain a
calibration curve to quantify the loaded TFD. With this value, encapsulation efficiency and
drug loading were calculated. Entrapment efficiency (EE) was calculated as the percentage
of entrapped TFD over the amount added initially for the preparation of nanocarriers. Drug
loading (DL) was expressed also as percentage and was the ratio between entrapped TFD and
the total weight of chitosan nanocarrier in the formulation.
Characterization of chitosan nanocarriers. The characterization of the obtained material
was carried out by means of Dynamic Light Scattering (DLS) analysis using a Brookhaven
90Plus DLS instrument and by means of Photo-Correlation Spectrosocopy (PCS) technique at
a concentration of nanocarriers of 0.15 mg/mL. Z-potential analysis was carried out using a
Plus Particle Size Analyzer (Brookhaven Instruments Corporation). In this case nanocarriers
were measured at a concentration of 5 μg/mL in 1mM KCl. The stability of TFD-loaded nano-
carriers toward aggregation in different media of biological interest was determined by DLS
and Z-potential analysis as previously reported. TFD-loaded CS-NCs were previously incu-
bated at 2 mg/mL and 37˚C in phosphate buffered saline (PBS), BBL Trypticase Soy Broth
(TSB), BBL Mueller Hinton II Broth Cation Adjusted medium (MHII) bacteria culture media
and pure water for comparison. They were measured immediately after entering in contact
with the medium, after 24 and 72 hours of incubation in terms of size (DLS) and surface
potential.
Bacterial strains and culture conditions
Staphylococcus aureus reference strains CECT-794 (Methicillin Sensitive S. aureus, ATCC
29213) and CECT 5190 (Methicillin Resistant S. aureus, ATCC 43300) were purchased from
the Spanish Collection of Type Cultures (CECT) and conserved in BBL Trypticase Soy Broth
in 15–17% glycerol stocks at -80˚C. For each experiment, the bacteria were transferred from
the frozen stock to a Columbia Agar plate with 5% Sheep Blood (BD), incubated overnight,
and one colony from that plate was transferred to 5 ml of BBL Trypticase Soy Broth, then incu-
bated 20h at 37˚C and used as the pre-inoculum for the experiments.
The MIC assays were performed with BBL Mueller Hinton II Broth Cation Adjusted
medium as recommended by the CLSI Standards for Antimicrobial Susceptibility Testing.
In vitro activity of vancomycin and TFD nanocomplexes vs Staphylococcus
aureus
The anti-microbial effects of vancomycin and TFD nanocomplexes were tested both separately
and in combination using a 96 well plate assay as previously described by Palomino et al. and
Ramon-Garcı´a et al.[26, 27] The checkerboard synergy test was used to study the interaction
between vancomycin and the TFD-nanocomplex against MSSA and later MRSA. Briefly, prior
to the addition of bacteria, serial dilutions of vancomycin were pipetted into wells along the
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vertical axis and serial dilutions of TFD-nanocomplexes were pipetted into wells along the hor-
izontal axis of a 96 well plate in parallel (S1A Fig). This allowed for the anti-microbial effect of
both vancomycin and TFD nanoparticles to be tested separately and combined. Specifically,
cNLC-TFD particles were tested using vancomycin concentrations ranging from 2.5 μg/ml-
0.04 μg/ml against TFD concentrations of 250 nM-0.5 nM. Bacteria were added to a final con-
centration of 105 cfu/mL, and the plates were incubated for 20 h at 37˚C. At this point, bacte-
rial inhibition was assessed using Alamar blue stain and recording a clear change in color from
blue (no growth) to pink (bacterial growth) (S1B Fig). The lowest concentration that prevents
a colour change was recorded as the MIC.
In the case of the MRSA cultures, bacterial growth inhibition was first assessed qualitatively
for a clear change in color (due to reduction of Alamar blue) and then was also quantified
using a microplate reader to determine absorbance at 570 nm and normalized to background
absorbance at 600 nm. In this case, percentage of bacterial growth was calculated with respect
to 100% growth in non-treated positive control bacteria. 96-well plate synergy assays were run
on 3 independent occasions for cNLC-TFD particles in both MSSA (and later MRSA) cultures
in order to establish vancomycin MICs and optimal TFD concentration.
Following checkerboard synergy assays, two representative concentrations of TFD were
selected for further experiments with MSSA strain CECT794: 125nM and 8nM using a
reduced number of samples in a 96 well plate format. This allowed for a reduced burden on
TFD stocks and offered a more streamlined method of testing non-specific TFD controls
These two TFD concentrations, in chitosan based CS-NC-TFDs (S2 Fig) and cNLC-TFD
nanoplexes (S3 Fig), were tested in combination with serial dilutions of vancomycin, ranging
from 2.5 to 0.16 μg/ml. These experiments were carried out in duplicate for a further 6 inde-
pendent experiments.
Cell viability assays
24 hours prior to testing, cells were seeded at a density of 1.25x 104 cells/ well in 96 well plates.
On the following day, cNLC-TFD nanocomplexes were formulated as previously described in
the methods section at an N/P ratio of 32. Nanocomplexes were added at a TFD range of con-
centrations from 500 to33 nM in complete cell culture media to either A549 adenocarcinomic
human alveolar basal epithelial cells (ATCC CCL-185) or primary Human Umbilical Vein
Endothelial Cells (HUVEC, Thermofisher Scientific) and incubated at 37˚C for 24 hrs. Follow-
ing incubation, cells were treated with WST-1 cell viability reagent (Roche, France) according
to the manufacturer’s instructions and cell viability was read using a Tecan microplate reader
at 450 nm. Cell viability of treated cells was compared against those of untreated controls and
cells treated with 100 μM staurosporine (Sigma-Aldrich) as a positive control and background
adjusted against cell medial only wells. Viability experiments were carried out in triplicate and
repeated 3 independent times.
Haemolysis assays
Haemolysis assays were performed using whole human blood samples which were obtained
from healthy donors (Etablissement Franc¸ais du Sang (EFS), Grenoble, France) and were col-
lected in citrate vacutainer tubes (Becton Dickinson, Le Pont de Claix, France). Informed
consent was given by blood donors according to the ethical and legal standards of our blood
supplier (EFS). Samples were used without any dilution and the blood tubes were delivered
three days after withdrawal and were kept at 4 ˚C in a fridge for storage. The experiments were
performed within three days after delivery.
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On the day of testing, cNLC-TFD complexes were formed as previously described and
diluted using the whole blood samples to a final volume of 500 μL and TFD concentrations
ranging from 33–500 nM. Samples were incubated at 37˚C for 90 min and then centrifuged
for 15 min at 800 g. The supernatant was collected and pipetted in duplicate into a 96 well
plate before being analyzed using a Tecan microplate reader at an absorbance of 540 nm. Per-
centage haemolysis was calculated by comparing against untreated controls. Samples were run
in triplicate and tested using 6 different donors.
Statistical analysis
Results were expressed as means ± standard error of the mean (SEM) for experiments using
GraphPad Prism 5 software. Two and one-way analysis of variance (ANOVA) for differences
between treatments with p-values < 0.05 considered significant, < 0.01 very significant
and< 0.001 highly significant.
Results
Loading efficiency and stability of cNLC-TFDs nanocomplexes in biological
buffers
Following formulation of the cNLC-TFD nanocomplexes, their size, polydispersity, zeta poten-
tial and complex stability were analyzed over a 72-hour time period in a variety of biological
buffers (Fig 3, S1–S3 Tables).
When analyzed for changes in nanocomplex size (Fig 3A), it was found that nanocomplexes
incubated in PBS buffer and TSB culture medium exhibited high levels of colloidal stability.
Fig 3. Stability analysis of cNLC-TFD nanocomplexes at N/P = 32 over a 72-hour timeframe in a variety of biological buffers. A) Size and polydispersity analysis
B) zeta potential analysis C) agarose gel electrophoresis analysis of nanocomplex integrity following incubation at 37˚C for 72 hours.
https://doi.org/10.1371/journal.pone.0220684.g003
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The size of nanocomplexes remained at approximately 45 nm throughout the 72 hours of incu-
bation with only minor increases in PDI observed for PBS treated samples (0.16 increasing to
0.20) and a slightly more substantial increase in the case of TSB treated samples (0.16 increas-
ing to 0.27). In contrast, nanocomplexes treated with A549 and HUVEC cells culture media
demonstrated an immediate increase in size and polydispersity. This was most evident in the
more complex HUVEC media, where nanocomplex size was 282 nm on the first day of analy-
sis and increased up to a maximum size of 409 nm 24 hours later. Size increases for A549
medium-treated nanocomplexes was less pronounced with a maximum size of 129 nm
recorded, however polydispersity indices for both media remained high throughout, with the
highest levels of 0.4 recorded in HUVEC media-treated samples after 72 hours.
On examination of the changes in zeta potential, evidence of buffer-specific behavior was
found in the results (Fig 3B). Specifically, cNLC-TFD nanocomplexes dispersed in PBS were
the only samples that retained a cationic surface charge throughout the 72 hours of testing.
This gave an early indication that the TFD was fully complexed by the cNLCs. In contrast,
all the cell and microbiology culture media displayed roughly the same anionic surface
charges (-3.6 mV to -4.1 mV) immediately after dispersion. cNLC-TFD nanocomplexes dis-
persed in culture media demonstrated further decreases at 24-hours incubation with the
lowest zeta potential recorded by nanocomplexes dispersed in A549 medium showing
-10.2 mV.
For the final aspect of cNLC-TFD characterization, the integrity of the nanocomplexes was
assessed following 72-hours incubation using agarose gel electrophoresis (Fig 3C). Nancom-
plexes were incubated in either equal volume of dH2O or 0.2 M NaOH for 5 minutes before
loading in the gel. Using this technique, it was demonstrated that cNLC-TFD nanocomplexes
were fully complexed at N/P = 32 and maintained their integrity for up to 72 hours in each bio-
logical buffer with the TFD oligonucleotide only being released from the nanocomplex follow-
ing the decomplexation in the presence of NaOH.
Determination of TFD entrapment efficiency and drug loading in chitosan
nanocarriers
Since TFD entrapment occurred during formulation of CS-NCs as opposed to after, it was nec-
essary to assess the TFD loading prior to advancing to stability studies. The entrapped TFD
was therefore quantified by agarose gel electrophoresis via precast gel staining with GelRed. A
simple, direct method was used to quantify the TFD entrapped in the CS-NCs. Chitosan nano-
carriers with the entrapped TFD were loaded into the gel at an adequate dilution without pre-
vious treatment, allowed to run to separate unentrapped TFD and then quantified against a
series of samples with known amounts of the free TFD.
Following visualization, a band appeared in CS-NC-TFD samples at the same distance as
free TFD loaded wells (Fig 4, S4 Table). This indicated that the entrapped TFD was released
from the nanocarrier, most likely due to a decrease in the electrostatic forces between TFD
and nanocarrier provoked by the alkaline pH of the electrophoresis buffer (pH 8.5). This was
further confirmed by loading a filtered suspension of the nanocarrier in their starting aqueous
medium in the gel. The absence of any band corresponding to the free TFD in this control con-
firmed that all the TFD molecules in the sample were associated to the nanocarrier and did not
exist as free molecules in the suspension. Empty nanocarriers at the same concentration as the
TFD-loaded samples were used as negative control.
Once it was established that the TFD was entrapped in the chitosan shell of the nanocar-
riers, the percentage entrapment efficiency and drug loading were calculated (Table 1, S5
Table). Differences in TFD loading were achieved during formulation by adding varying
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amounts of TFD and relating the final amount of entrapped TFD against carrier mass (as
opposed to %w/w of starting materials).
On analysis, it was determined that addition of 50 μg TFD resulted in a percentage drug
loading (DL) of 0.071% and a percentage encapsulation efficiency (EE) of 42%. When doubling
the amount of TFD to 100 μg, the DL increased (0.138%) however EE remained at 44%. How-
ever, when doubling the amount of TFD to 200 μg, the DL obtained was far from being dou-
bled (0.190%) and the EE decreased (24%). This was understood that beyond addition of
100 μg TFD to the synthesis, the saturation point was reached and the nanocarrier was unable
to entrap any further TFD. In view of these results, nanocarriers synthesized by the addition of
100 μg TFD were chosen as the best candidates for further studies, since they presented a high
DL value without compromising the EE.
Fig 4. Agarose gel electrophoresis to quantify the TFD entrapped in chitosan nanocapsules. A) Addition of 50 μg TFD. Lane 1, empty CS-NCs; lanes 2–7, free TFD
calibration; lane 8, empty well; lanes 9–12, TFD-CS-NCs diluted 1:2; lane 13, filtered TFD-CS-NCs. B) Addition of 100 μg TFD. Lanes 1–4, free TFD calibration; lanes
5–6, empty CS-NCs; lanes 7–9, TFD-CS-NCs diluted 1:5; lanes 10–12, TFD-CS-NCs diluted 1:10; lane 13, filtered TFD-CS-NCs. C) Addition of 200 μg TFD. Lane 1,
empty CS-NCs; lanes 2–7, free TFD calibration; lanes 8–11, TFD-CS-NCs diluted 1:8; lane 12, filtered TFD-CS-NCs.
https://doi.org/10.1371/journal.pone.0220684.g004
Table 1. Drug loading and entrapment efficiency of TFD-CS-NCs.
TFD initially added (μg) 50 100 200
Drug loading (DL) % 0.071 ± 0.007 0.138 ± 0.016 0.190 ± 0.049
Entrapment efficiency (EE) % 42 ± 4 44 ± 5 24 ± 6
https://doi.org/10.1371/journal.pone.0220684.t001
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Stability of TFD-loaded chitosan nanocarriers in biological buffers
Four different media have been used for the study of nanocarriers stability: water, phosphate
buffer saline (PBS), tryptic soy broth (TSB) and Mueller Hinton II (MHII) culture media.
MilliQ water was chosen because it is the storage medium for chitosan nanocarriers. PBS is a
commonly used isotonic buffered salt solution used for intravenous injection. TSB is a gen-
eral-purpose medium that is routinely used to grow most bacteria and MHII is the medium
used for antibiotic susceptibility testing with methicillin-resistant strains of S. aureus. In con-
trast to cNLC-TFD formulations, TFD-CS-NCs were not tested in A549 and HUVEC as they
were not brought forward for in vitro testing in mammalian culture as they were discarded
due to their low levels of antimicrobial effect.
When analyzed for particle size (Fig 5A, S6–S8 Tables), during the first 24 h the hydrody-
namic diameter was slightly decreased independently of the buffer used for the incubation.
Mean diameters were slightly smaller at 24 h than at time 0 but still comprised between 300
and 400 nm. After 72 h nanocarriers in water exhibited a similar mean diameter but nanocar-
riers incubated in PBS, TSB and MHII showed a pronounced decrease in their size, especially
in TSB, with a mean diameter of 175 nm and with mean diameters of 250 nm in PBS and
MHII. Size distribution of TFD-loaded chitosan nanocarriers is quite polydisperse in aqueous
solution. A low percentage of aggregates or bigger nanoparticles was always detected but it was
considered non-significant for the aim of this study.
Z-potential analysis, performed after incubation of nanocarriers in different media, evi-
denced some buffer-specific behavior that was attributed to a masking effect on nanocarriers
surface due to the adsorption of ions and proteins contained in these media (Fig 5B).
Fig 5. Stability analysis of TFD-CS-NC nanocarriers over a 72-hour timeframe in a variety of storage and biological buffers. A) Size analysis B) zeta potential
analysis and C) polydispersity index.
https://doi.org/10.1371/journal.pone.0220684.g005
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Specifically, nanocarriers dispersed in water presented a Z-potential value slightly negative
(around -10 mV) that maintained constant during 72 h incubation. On the contrary, the sur-
face potential of nanocarriers in culture media (TSB and MHII) was quite lower (between -38
and -50 mV) and even lower in PBS since in this buffered medium the value maintained
almost constant around -60 mV during 72 h.
In vitro activity of vancomycin in combination with TFD-nanoplexes vs S.
aureus (MSSA and MRSA)
To determine the independent and combined antimicrobial abilities of vancomycin and the
TFD-nanocomplexes, two strains of S. aureus were used. Initial experiments were undertaken
using the MSSA reference strain CECT794, which is indicated by the CLSI guide as a standard
in drug susceptibility assays. Following this, formulations displaying anti-microbial effects
were brought forward for testing in CECT5190, which is the methicillin resistant strain com-
monly used for drug susceptibility assays.
TFD-nanocomplex/vancomycin synergy assays in CECT 794 MSSA. From visual assess-
ment of the plate following Alamar blue addition, cNLC-TFD nanocomplexes did not demon-
strate any antibacterial activity by themselves in concentrations up to 500 nM of TFD (S1 Fig).
However, the presence of cNLC-TFD nanocomplexes in combination with vancomycin,
resulted in a 50% decrease in the MIC of vancomycin, compared to the antibiotic alone from
0.6 μg/ml to 0.3 μg/ml. This was only observed when the TFD was complexed with the cNLC
and this effect was clearly dependent on the concentration of TFD. When the amount of TFD
was 66 nM and above, the efficacy of vancomycin was enhanced but below this concentration
there was no effect evident.
Two representative concentrations of TFD-NC were selected for further experiments with
CECT794: 125 nM and 8 nM. These were tested in standard growth inhibition tests with
CECT 794 together with sub-MIC amounts of vancomycin. Similarly, the chitosan-based
CH-NC-TFD nanocarriers were also tested in this reduced sample format. Unfortunately, the
same result was not obtained for the chitosan nanocarriers, as they did not show this boosting
effect for the antibiotic. (Table 2). This experiment was repeated 6 times with identical results
(S2 Fig).
It was also confirmed that free WalR TFD non-associated to any nanocarrier did not have
any boosting effect on vancomycin (S3 Fig), reinforcing the requirement of the DNA sequence
to be complexed for efficient delivery. In addition, the cNLC without any TFD associated, at a
concentration equal to that present when a concentration of 125 nM TFD is achieved, does
not modify the efficiency of vancomycin, thus corroborating that the observed effect is due to
the oligonucleotides. Considering the lack of efficacy observed in the current guise of the chit-
osan-based nanocarriers for TFD delivery, it was decided to continue to MRSA studies with
only the cNLC complexed TFDs.
TFD-nanocomplex/vancomycin synergy assays in CECT 5190 MRSA. Following initial
success with the MSSA strain, the cNLC-TFD nanocomplexes were assayed to determine if the
Table 2. MIC values of vancomycin and either cNLC-TFD or CH-NC-TFD nanocomplexes as well as relevant controls (n = 6) against S. aureus CECT794 strain
using reduced sample assay.
MIC vancomycin (μg/ml)
vanco alone + WalR-TFD 125nM + WalR-TFD 8nM + empty carrier + WalR-TFD non- encapsulated + non-specific (WhiB7) TFD
cNLC 0.6 0.3 0.6 0.6 0.6 0.6
CH-NC 0.6 0.6 0.6 0.6 0.6 0.6
https://doi.org/10.1371/journal.pone.0220684.t002
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boosting effect when co-administered with vancomycin was also possible in MRSA. Vancomy-
cin and cNLCs were tested simultaneously in a checkerboard synergy assay as demonstrated
for MSSA and observed after 24 hours for changes in the MIC of vancomycin. The MRSA
plates were analyzed using spectrophotometry following Alamar blue addition to establish if
there were any changes in MRSA growth.
Using this method, it was found that while there was not total inhibition of the MRSA
growth, there were significant decreases in viability observed when the samples were treated
with cNLC-TFD nanocomplexes in the presence of vancomycin. For this strain, the MIC of
vancomycin was 1.2 μg/ml and so at a concentration of 0.6 μg/ml of vancomycin alone, the
bacterial growth was found to be 90% (± 4.30%) of the untreated control. In contrast, in the
presence of cNLC containing 125nM of TFD, the bacterial growth for 0.6μg/ml of vancomycin
was reduced to 46% (± 13.41%) with respect to untreated bacteria (Fig 6, S9 Table). This indi-
cated that, while not completely eradicating the MRSA, the potency of the vancomycin was sig-
nificantly increased when combined with cNLC-TFD nanocomplexes.
Mammalian cell viability following administration of cNLC-TFD
nanocomplexes
In anticipation of future testing in MRSA infected in vivo systems, mammalian cell viability
levels were tested over a TFD dose range of 500 nM– 33 nM. Nanocomplexes toxicity was
assessed using the A549 alveolar cell line and primary human vascular endothelial cells
(HUVEC) at 24 hours post-administration (Fig 7, S10 Table). This allow analysis in both cell
line and primary cell types as well as being reflective of cell types where local (pulmonary) and
systemic (circulatory system) MRSA infections may occur.
On analysis of cNLC-TFD toxicity in HUVEC cells (Fig 7), it was found that there were
very low levels of toxicity observed. Viability was close to or above 100% in all doses tested
with cells treated using 500 nM TFD/252 μg cNLC concentration (four times above that
needed for enhancing vancomycin antimicrobial activity) remaining at 97% viability. Simi-
larly, A549 alveolar epithelial cells demonstrated no decreases in cell viability at all dose ranges
tested (Fig 7). Finally, in all cell lines tested, cyclosporine positive controls were observed to be
functioning normally with all cell lines demonstrating significant decreases in viability. These
results also further emphasised that the cNLC-TFD nanocomplex doses used to enhance the
antimicrobial effect were via TFD-mediated transcription inhibition and not simply function-
ing through a particle-mediated cytotoxic effect.
Erythrocyte integrity following incubation with cNLC-TFD nanocomplexes
Due to the likelihood that any future in vivo administration of cNLC-TFD would occur
through IV injection or perfusion, the potential for lysis of circulating erythrocytes was also
assessed in vitro. Following 90 minutes of incubation and separation of the supernatant, it was
found that cNLC-TFD nanocomplexes resulted in only low levels of haemolysis (Fig 8, S11
Table). The highest value recorded was 12.55% (±7.35%) haemolysis in the 500 nM TFD con-
centration sample, while haemolysis produced by lower concentrations of cNLC-TFD were
below 10%. Furthermore, there was no statistically significant differences determined to be
present between the dose ranges.
Discussion
Overcoming resistance among pathogenic bacteria, especially MRSA, remains a priority for
the development for the next generation of antimicrobial compounds. Unfortunately, mecha-
nisms of drug resistance have been found to be highly adaptable and diverse in nature. These
Enhancing vancomycin at the genetic level with transcription factor decoys
PLOS ONE | https://doi.org/10.1371/journal.pone.0220684 September 3, 2019 14 / 24
include target modifications (commonly through the development of mutations) that prevent
binding of antimicrobials, production of enzymes that modify the antimicrobial to prevent
drug binding, or decreasing the effective concentration of antimicrobials through efflux
pumps to name but a few [1, 28].
Normally, the introduction of a novel antimicrobial molecule is followed immediately by
the selection of antimicrobial resistant strains. Recently, this has already become apparent in
the case of the small molecule drug bedaquiline. Approved for multi-drug-resistant tuberculo-
sis in 2012, resistant variants are now being described [29–31]. Therefore, instead of entering
Fig 6. Synergy assay demonstrating enhanced antimicrobial effect against MRSA strain CECT 5190 when read at 570 nm. From left,
untreated MRSA controls, MRSA treated with sub-MIC dose of 0.6 μg/ml vancomycin, MRSA treated with cNLC-TFD nanocomplexes at a
TFD concentration of 125 nM and MRSA treated with dual therapy of 0.6 μg/ml free vancomycin and cNLC-125nM TFD nanocomplexes
(n = 3 ±SEM, �P<0.05, ��P<0.01, one-way ANOVA).
https://doi.org/10.1371/journal.pone.0220684.g006
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into the typical cycle of new antimicrobial—resistance, our study attempted to address the
issue at the genetic level, by using TFDs targeting essential transcription factors. This was
with the rationale that, since the TFD DNA sequence being introduced exists normally in S.
aureus, it will be much less likely to develop new resistance mechanisms to its presence. Fur-
thermore, in our study, the specific TFD sequence binds the transcription factor WalR which
is the regulator of the WalK/R two-component regulatory system in S. aureus. This protein is
highly conserved and essential for the viability of this microorganism. WalR plays a key role in
controlling cell wall metabolism and membrane composition, and it has been reported to be
implicated in resistance to vancomycin [20, 21, 32]. TFDs as a gene inhibition strategy were
especially attractive in prokaryotes given that, due to the cytoplasmic location of bacterial
genomic DNA, they would only need to get inside the bacterial cells to exert an effect (rather
than traverse the additional barrier of the nuclear membrane as in eukaryotes). While this ben-
efit is counterbalanced somewhat by the presence of the bacterial cell wall, it has previously
been demonstrated that it is possible fully internalize nucleic acid-nanoparticles into Gram-
positive bacteria [33].
Considering this, to protect against degradation and aid in overcoming the bacterial cell
wall and membrane permeability barriers, TFDs were complexed to two different nanocar-
riers. Both consisted of a nanoemulsion core surrounded either by a combination of PEG and
cationic lipids (cNLCs) or a chitosan shell (CS-NCs). These were complexed with the TFD in
two different fashions, with cNLCs being complexed separately with TFDs following nanopar-
ticle formulation and CS-NCs combining with TFD during formulation. Following complexa-
tion, both were analysed for particle behavior and, in the case of the cNLC-TFDs, high levels of
stability over 72 hrs was observed. cNLC-TFD sizes in PBS remained stable in PBS and TSB up
to 72hrs with more variation seen in the samples incubated in mammalian cell culture media.
This was further reflected on examination of the zeta potential of the cNLC-TFD nanocom-
plexes, the cationic nature of the two was evident in PBS further demonstrating that all nega-
tively charged TFD was effectively condensed at N/P = 32. When tested in the more complex
A549, HUVEC and TSB media, more erratic surface charges were recorded over time. All
three exhibited negative surface charge from the start with TSB and A549 media increasing in
Fig 7. WST-1 assay analysis of cell viability following cNLC-TFD nanocomplex administration in A549 and HUVEC cells. Viability was assessed as percentage
change against untreated negative control cells including cyclosporine positive control samples (PC). (n = 3 ±SEM).
https://doi.org/10.1371/journal.pone.0220684.g007
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zeta potential over 72 hrs and samples in HUVEC continuing to decrease in zeta potential.
This is highly likely to be related to protein and sugar aggregation on the particles in all cases
[34] with the differences between groups depending on the specific components of each
media. For example, the presence of growth factors in HUVEC medium which are absent
from the A549 and TSB.
Most importantly, following gel electrophoresis analysis, it was especially evident that
cNLC-TFD nanocomplex integrity was maintained in all buffers tested. Specifically, when
cNLC and TFDs were decomplexed in the presence of NaOH, TFD demonstrated similar
bands to those of control TFD. This was in keeping with previous work by the group in devel-
oping highly stable nanoemulsion based nanoparticles [35–37] and indicated that cNLCs-TFD
nanocomplexes were not destroyed in in vitro test conditions.
Since TFD oligonucleotides were added to CS-NCs prior to formulation being finalized, it
was necessary to determine the optimal loading efficiency prior to stability analysis. This was
Fig 8. Percentage of haemolysis from whole human blood following incubation with cNLC-TFD nanocomplexes. Samples were incubated for 90
minutes at 37˚C (n = 6 ±SEM, one-way ANOVA).
https://doi.org/10.1371/journal.pone.0220684.g008
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in contrast to cNLCs where the TFD is added after formulation and complexation efficiency
was considered near-total based on their cationic surface charge in PBS and signal quenching
under UV following electrophoresis. Therefore, when CS-NC-TFD nanocomplexes were
examined following formulation, it was quickly determined that a saturation point in TFD
loading efficiency was reach when any more than 100 μg of TFD was loaded per formulation.
When TFD loading was kept below this cut off, entrapment efficiencies were found to be as
high as 44% with the balance of this deemed lost during production. When analyzed for phy-
sico-chemical properties, CS-NC-TFD demonstrated high levels of stability up to 24 hrs as can
be expected when its inner core is based on the colloidal stability of a nanoemulsion/solid lipid
nanoparticle [38, 39].
The decrease in size observed after 72h incubation of TFD-loaded nanocarriers in PBS, TSB
and MHII, could be attributed to a destabilization effect of the components of the medium
resulting in aggregation upon interaction with ions and proteins leading to a general decrease
of mean hydrodynamic diameter. Similarly, the decrease in Z-potential value is in agreement
with the high ionic strength of the medium. These results confirmed the interaction of
medium components on nanocarrier surface which have been previously described as having
dramatic impacts on particle size and surface charge [34].
Following initial characterization of both TFD nanocomplexes, these were first tested for
antimicrobial activity against a methicillin susceptible strain of S. aureus. It was thought pru-
dent to begin with a more treatable strain of S. aureus to establish the potency of the TFD-
nanocarrier system in general. It was also thought logical to assess the activity of the TFD-
nanocarriers alone and in the presence of vancomycin. This is since it is likely that any antimi-
crobial gene therapy treatments to be tested in patients will likely be administered in conjunc-
tion with the best available care (i.e. vancomycin). By use of the checkerboard assay, it was
possible to rapidly assess the in vitro efficacy for both vancomycin and TFD-nanocarriers both
alone and in tandem. From initial testing in MSSA, the cNLC-TFDs in the absence of vanco-
mycin were not found to totally eliminate the bacteria. This made it impossible to determine a
MIC using only the cNLC-TFDs at the concentrations tested. To date, TFDs have been suc-
cessfully delivered to a range of mammalian cells (comprehensively reviewed by Ulasov et al.
[40]) but remaining under-investigated in bacterial culture. At the time of writing, TFDs have
been successfully delivered to Escherichia coli and Clostridium difficile using highly cationic
carriers [17, 41, 42] but have yet to be established in S. aureus cultures.
However, on co-administration with vancomycin, it was found that the cNLC-TFDs exhib-
ited a “boosting effect” and the MIC of vancomycin was decreased by 50% using TFD concen-
trations as low as 63 nM. While this could not be described as synergy at this point since the
TFD did not exhibit antimicrobioal effect by itself, it was clear that the increase in efficacy was
due to the cNLC-TFD reaching its site of action and consequently increasing vancomycin sus-
ceptibility. This was made clear when the increase in efficacy was not observed when a non-S.
aureus specific TFD, cNLC alone or WalR-TFD non-encapsulated were used instead. Unfortu-
nately, no antimicrobial effect was observed using the CS-NC-TFD nanocomplexes, either
alone or in combination with vancomycin. This was surprising given the known suitability of
chitosan particles as a delivery agent for antimicrobials against S. aureus [43]. Considering the
anionic surface charge observed for the CS-NC-TFDs, it is likely that these nanocarriers were
electrostatically repelled from the bacteria and were unable to exert an effect as has been previ-
ously demonstrated in mammalian cells [44, 45] and in MRSA [46]. Combined with the chal-
lenges posed by the rapid doubling time of bacteria, it is likely that any positive effects elicited
by the few successful CS-NC-TFD transfections would be rapidly eclipsed by unaffected repli-
cating bacteria. Therefore, further optimisation of this nanocarrier was deemed necessary before
reapplying it to TFD delivery to S. aureus and it was not progressed any further in this study.
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Having demonstrated a clear ability to enhance the efficacy of vancomycin in MSSA strains,
the cNLC-TFDs were then progressed to antimicrobial activity experiments involving MRSA.
We found that the MRSA strain was less susceptible (MIC 1.2 μg/mL) to vancomycin than the
MSSA strain (MIC 0.6 μg/mL), and it was hypothesized that this finding represented a general
decrease in susceptibility, and thus immediately represented a more challenging environment
for TFD-mediated therapy.
On visual inspection, the ability of cNLC-TFDs to enhance the potency of vancomycin was
not immediately clear as was the case with MSSA. However, absorbance analysis demonstrated
that antimicrobial effect was very clearly retained while not entirely inhibiting growth of the
bacteria. Specifically, sub-MIC (0.6 μg/ml) vancomycin and cNLC-TFD combination therapy
resulted in significantly higher levels of bacterial growth inhibition compared to 0.6 μg/ml
vancomycin treatment alone (54% vs 10% respectively). Furthermore, absorbance readings
also indicated that cNLC-TFD administration alone was capable of up to a 32% reduction in
MRSA viability, thus demonstrating a standalone ability of the cNLCs to promote transport
of TFD molecule through the bacterial cell wall and membrane. This gave further weight to
initial theories that the TFD was being successfully delivered and was biologically active but
was insufficient to clear the bacteria on its own due to the logarithmic growth of the S. aureus.
It was also noted that while the combined therapy was not significantly better than cNLC-TFD
alone, cNLC-TFD administered on its own yields no significant improvement in antimicrobial
effect compared to vancomycin. In comparison, the dual therapy approach is significantly bet-
ter than vancomycin alone beyond the sum of its parts. It is now critical to recognize that in
any clinical setting the rationale is not to add vancomycin to improve cNLC-TFD efficacy but
rather the inverse. This is especially so given that any potential clinical trial will strive to con-
tinue best clinical care in conjunction with the test compound.
Therefore, while it was not possible to claim synergy in terms of relative MICs of vancomy-
cin and cNLC-TFDs, it is possible to make this claim in terms of percentage rates of bacterial
growth inhibition. Both sub-MIC vancomycin and cNLC-TFDs elicit an antimicrobial effect
in MRSA and that the combination of the two results in higher levels of growth inhibition than
the sum of their parts. This effect is thought to occur since both vancomycin and the TFDs
inhibit S. aureus formation of the cell wall. The TFDs inhibit the WalR pathway as previously
described, and vancomycin has long been known to inhibit the second stage of cell wall synthe-
sis and may also affect permeability of the cell membrane [9, 10].
Finally, to ensure that administered cNLC-TFDs do not result in off-target effects or cyto-
toxic events, these were tested in relevant primary and cell line samples. All similar concentra-
tions as used to produce anti-bacterial activity were found to result in no decrease in cell
viability. Furthermore, haemolysis levels were minimal up to 500 nM concentrations of
cNLC-TFD. All samples were roughly at 10% haemolysis and the preferred dose of 125 nM
TFD was below 5% which was within the acceptable limits for nanoparticle-induced haemoly-
sis [47, 48]. Thus, this study has developed a dual delivery approach that demonstrates a clear
improvement over current best practice and is well tolerated by mammalian cells.
Conclusions
Co-administration of nanomedicine-based products and free small molecule drugs remains an
under-explored option but is a logical progression in the clinical development of nanomedi-
cines. Considering that antimicrobial resistance is a persistent and constantly evolving issue in
treating bacterial infection combined with the lack of novel small molecule drugs in the pipe-
line, serious consideration needs to be given to methods that increase the potency of currently
available drugs. In this study, it was found that TFD molecules complexed with suitable
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nanocarriers are capable of significantly improving the potency of vancomycin against MSSA.
When dual therapy was applied against MRSA cultures, a clear synergistic effect in decreasing
bacterial growth was evident. This approach has remained virtually unreported but highlights
a new possibility in overcoming resistance mechanisms in S. aureus. Optimizations of the
nanocarrier composition and the sequence and structure of the TFD molecule are being car-
ried out in order to further improve their combined efficacy against MRSA. Following this, it
is hoped that in-depth screening in biofilm models and in vivo infection studies may occur.
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S1 Fig. Synergy assay demonstrating enhanced bacterial killing of S. aureus strain CECT
794 following co-administration of free vancomycin (μg/ml) and cNLC-TFD nanocom-
plexes. A) 96 well plate layout and B) photograph of assay plate after addition of Alamar blue,
revealing the enhanced vancomycin susceptibility of S. aureus in the presence of TFD at the
point of the blue arrow (n = 4).
(TIF)
S2 Fig. Reduced sample assay investigating bacterial killing of S. aureus strain CECT 794
following co-administration of free vancomycin (μg/ml) alone (rows A+B 1–5), combined
with WalR-specifc TFD CS-NC-TFD nanocomplexes (rows C-F 1–5), combined with non-
WalR specific/non-targeting TFD (rows A+B 7–11) and free non-WalR TFD (rows C-F
7–11). A) 96 well plate layout and B) photograph of assay plate after addition of Alamar blue,
revealing no improvement in MIC using WalR TFD-CS-NCs at 125 nM (rows C+D 1–5) or 8
nM TFD (rows E+F 1–5) (n = 6).
(TIF)
S3 Fig. Reduced sample assay investigating bacterial killing of S. aureus strain CECT
794 following co-administration of free vancomycin (μg/ml) and non-WalR specific
cNLC-TFD nanocomplexes. A) 96 well plate layout and B) photograph of assay plate after
addition of Alamar blue, revealing no improvement in MIC using WhiB7 TFD-cNLCs at 125
nM (rows C+D 1–5) (n = 6).
(TIF)
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